EAGLE Crash Lands: AstraZeneca's Imfinzi/Tremelimumab Continues To Disappoint

07 Dec 2018

The latest failure of the combination of AZ's PD-L1 inhibitor and its CLTA4 inhibitor is in advanced head and neck cancer. It follows recent failures of the MYSTIC and ARCTIC trials in lung cancer.

Eagle — AstraZeneca's EAGLE has not soared • Source: Shutterstock

EAGLE Crash Lands: AstraZeneca's Imfinzi/Tremelimumab Continues To Disappoint

More from Immuno-oncology

More from Anticancer